<?xml version="1.0" encoding="UTF-8"?>
<p id="par0075">Remdesivir, a nucleotide analog antiviral inhibitor that may compete for RdRp, was designed for the Ebola virus and was with efficient against MERS and SARS [
 <xref rid="bib0400" ref-type="bibr">80</xref>]. Remdesivir has been reported to inhibit 
 <italic>in vitro</italic> SARS-CoV-2 proliferation and therefore has clinical therapeutic potential [
 <xref rid="bib0405" ref-type="bibr">81</xref>]. Recently, Remdesivir was used in a clinical trial including 53 COVID-19 patients. Results showed clinical improvement in 36 of the 53 patients (68%). However, this drug needs to be used especially for patients not receiving invasive ventilation as the mortality rate was 18% when receiving ventilation, compared to 5% when not receiving [
 <xref rid="bib0410" ref-type="bibr">82</xref>].
</p>
